CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced the presentation of preclinical data from its Trofex development program for two promising molecular imaging pharmaceutical candidates, MIP-1072 and MIP-1095, for potential use in the detection and monitoring of prostate cancer. Both compounds are radiolabeled small molecules that target prostate-specific membrane antigen (PSMA), a protein that is highly expressed by prostate tumor cells. Based on these and other studies, Molecular Insight plans to begin exploratory clinical trials in the first half of 2008 with both compounds to select a candidate for further clinical development and commercialization.
